You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
L
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
Not yet recruiting
  • Lymphoma, Non-Hodgkin Lymphoma, B-Cell
  • BAFF CAR-T
  • (no location specified)
2022-04-01
Apr 1, 2022
C
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • +3 more
    • (no location specified)
    2021-07-20
    Jul 20, 2021
    V
    Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma
    Not yet recruiting
    • Non-hodgkin Lymphoma,B Cell
    • Vaccination Failure
    • Immunological analyses
    • (no location specified)
    2021-09-13
    Sep 13, 2021
    M
    Family Study of Lymphoproliferative Disorders
    Recruiting
    • Lymphoma, Non-Hodgkin
    • +4 more
      • Rochester, Minnesota
        Mayo Clinic
      2021-08-30
      Aug 30, 2021
      U
      TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma
      Active, not recruiting
      • Non Hodgkin Lymphoma
      • Cologne, Germany
      • +1 more
      2022-03-02
      Mar 2, 2022
      S
      Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
      Recruiting
      • Lymphoma, Non-Hodgkin
      • Lymphoma, Hodgkin
      • Seoul, Korea, Republic of
        Samsung Medical Center
      2021-03-21
      Mar 21, 2021
      U
      Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma - 2021
      Completed
      • Hodgkin's Lymphoma
      • Lymphoma, Non-Hodgkin
      • Ann Arbor, Michigan
        University of Michgan Comprehensive Cancer Center
      2021-12-03
      Dec 3, 2021
      C
      CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
      Recruiting
      • Lymphoma, Non-Hodgkin
      • +6 more
      • CB-010
      • +2 more
      • Scottsdale, Arizona
      • +5 more
      2022-04-05
      Apr 5, 2022
      M
      A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) - 2020
      Terminated
      Has Results
      • Lymphoma, Non-Hodgkin
      • Lymphoma, Follicular, Marginal Zone
      • Nagoya-shi, Aichi, Japan
      • +3 more
      2021-08-17
      Aug 17, 2021
      D
      A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma - 2021
      Completed
      Has Results
      • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      2022-03-15
      Mar 15, 2022
      A
      Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG
      Not yet recruiting
      • Lymphoma, Non-Hodgkin
      • Lymphoma, Hodgkin
      • intervention
      • (no location specified)
      2022-02-09
      Feb 9, 2022
      U
      Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
      Active, not recruiting
      • Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
      • Refractory Transformed B-cell Non-Hodgkin Lymphoma
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      2022-01-20
      Jan 20, 2022
      B
      Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
      Recruiting
      • Diffuse Large B-Cell Lymphoma
      • +14 more
      • La Jolla, California
      • +1 more
      2022-01-10
      Jan 10, 2022
      W
      Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
      Active, not recruiting
      • Lymphoma, Non-Hodgkin
      • Stem cell infusion
      • +5 more
      • Saint Louis, Missouri
        Washington University
      2022-01-12
      Jan 12, 2022
      C
      Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma - 2020
      Terminated
      Has Results
      • Hodgkin Disease
      • Lymphoma, Non-hodgkin
      • New York, New York
        Columbia University Irving Medical Center - Center for Lymphoid
      2021-06-28
      Jun 28, 2021
      N
      Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
      Completed
      • Leukemia
      • +3 more
        • Bethesda, Maryland
          National Cancer Institute (NCI), 9000 Rockville Pike
        2022-04-07
        Apr 7, 2022
        U
        Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
        Recruiting
        • Follicular Lymphoma
        • +2 more
        • Laboratory Biomarker Analysis
        • Pembrolizumab
        • Seattle, Washington
          Fred Hutch/University of Washington Cancer Consortium
        2021-12-15
        Dec 15, 2021
        H
        A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
        Recruiting
        • Lymphoma, Non-Hodgkin
        • Melbourne, Victoria, Australia
        • +1 more
        2022-03-21
        Mar 21, 2022
        S
        Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
        Active, not recruiting
        • CD20-positive Non-Hodgkin Lymphoma
        • Rituximab + MG4101
        • Seoul, Korea, Republic of
          Seoul National University Hospital
        2022-02-04
        Feb 4, 2022
        S
        Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
        Recruiting
        • High Grade B-Cell Lymphoma, Not Otherwise Specified
        • +4 more
        • Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
        • R-CHOP; R-DA-EPOCH; R-HD MTX
        • Jinan, Shandong, China
          Department of Hematology, Shandong Provincial Hospital
        2021-12-07
        Dec 7, 2021
        N
        Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
        Withdrawn
        • Diffuse Large B-Cell Lymphoma (DLBCL)
        • Tisagenlecleucel
        • (no location specified)
        2022-02-25
        Feb 25, 2022
        T
        Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose - 2021
        Completed
        • Hodgkin Lymphoma, Adult
        • Non-Hodgkin Lymphoma, Adult
        • SPECT with 99mTc-1-thio-D-glucose
        • Tomsk, Russian Federation
          TomskNRMC
        2021-03-30
        Mar 30, 2021
        A
        RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy
        Not yet recruiting
        • Non Hodgkin Lymphoma
        • (no location specified)
        2022-03-31
        Mar 31, 2022
        H
        Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma
        Recruiting
        • Non-hodgkin's Lymphoma
        • CD19+22 CAR-T cells
        • Langfang, Hebei, China
          Hebei Yanda Ludaopei Hospital
        2022-01-11
        Jan 11, 2022
        M
        Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
        Recruiting
        • Aggressive Non-Hodgkin Lymphoma
        • +5 more
        • Laboratory Biomarker Analysis
        • +2 more
        • Rochester, Minnesota
          Mayo Clinic
        2022-03-25
        Mar 25, 2022